These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35083900)

  • 1. Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.
    Zhang Q; Ma C; Dong R; Xiang W; Li M; Ma Z; Yang Q
    Yonsei Med J; 2022 Feb; 63(2):148-157. PubMed ID: 35083900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.
    Zhan S; Liu C; Li N; Li T; Tian Z; Zhao M; Wu D; Chen M; Zeng Z; Zhuang X
    Therap Adv Gastroenterol; 2022; 15():17562848221116666. PubMed ID: 36082178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.
    Zhang M; Liu J; Liu T; Han W; Bai X; Ruan G; Lv H; Shu H; Li Y; Li J; Tan B; Zheng W; Xu H; Zheng W; Yang H; Qian J
    J Gastroenterol Hepatol; 2022 Apr; 37(4):608-619. PubMed ID: 34894004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet's uveitis: A systematic review and meta-analysis.
    Guan X; Zhao Z; Xin M; Xia G; Yang Q; Fu M
    Int J Rheum Dis; 2024 Feb; 27(2):e15096. PubMed ID: 38402428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
    Miyazaki H; Watanabe D; Okamoto N; Tokunaga E; Ku Y; Takenaka H; Hoshi N; Ooi M; Kodama Y
    BMC Gastroenterol; 2022 Mar; 22(1):149. PubMed ID: 35346067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.
    Han SJ; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    Yonsei Med J; 2023 Feb; 64(2):111-116. PubMed ID: 36719018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.
    Kambayashi H; Omori T; Saito S; Murasugi S; Kashiwagi H; Ito A; Yonezawa M; Nakamura S; Tokushige K
    Intern Med; 2020; 59(19):2343-2351. PubMed ID: 32999263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet's disease: A systematic review of controlled trials.
    Zhou X; Shi X; Ren Y; Yan T; Ye Q
    Front Pharmacol; 2022; 13():912906. PubMed ID: 36060006
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative study of corticosteroid monotherapy, and TNF inhibitors with or without corticosteroid in patients with refractory entero-Behcet's disease.
    Miyagawa I; Nakano K; Iwata S; Nakayamada S; Saito K; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Tanaka Y
    Arthritis Res Ther; 2019 Jun; 21(1):151. PubMed ID: 31228955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcomes of intestinal Behçet's disease: A 30-year cohort study at a tertiary hospital in South Korea.
    Park J; Park SJ; Park JJ; Kim TI; Cheon JH
    J Gastroenterol Hepatol; 2023 Mar; 38(3):386-392. PubMed ID: 36346041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
    Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
    Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
    Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
    BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
    Li R; Li X; Zhou H; Shi Y; Wang F; Wu T; Liang J
    Front Immunol; 2023; 14():1205046. PubMed ID: 37287984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
    Park Y; Cheon JH
    Curr Gastroenterol Rep; 2020 Mar; 22(5):24. PubMed ID: 32193746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
    Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
    Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
    Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
    BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 blockade for Behçet's disease: review on 31 anti-TNF naive and 45 anti-TNF experienced patients.
    Arida A; Saadoun D; Sfikakis PP
    Clin Exp Rheumatol; 2022 Sep; 40(8):1575-1583. PubMed ID: 36106545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
    Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
    Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
    Park J; Cheon JH
    Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of TNF inhibitors in patients with Behçet's disease: Retrospective study from eastern Turkey.
    Bektaş M; Özer MD; Oğuz E
    Clin Immunol; 2024 Jul; 264():110239. PubMed ID: 38734038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.